Mylan Pharmaceuticals Issues Recall for BP Meds

Mylan Pharmaceuticals

Pharmaceutical company Mylan Pharmaceuticals has issued a recall for three of their blood pressure medications, over a possible cancer causing ingredient present in the medication.

What medications are being recalled?

Valsartan pills are part of the recall for Mylan Pharmaceuticals. After being tested, the medications were found to contain small amounts of NDEA or N-nitrosodiethylamine within valsartan, which is a potential cancer causing agent in humans.

What do these drugs do?

The type of medications being recalled, are part of a group of blood pressure medications known as angiotensin II receptor blockers. The medications both widen and relax blood vessels, which help bring an individual’s blood pressure down.

Where did the recall originate from?

Investigators from the Food and Drug Administration (FDA) have tracked the compromised drugs to drug factories in China as well as India. Both factories supply a large percentage of generic drugs to the global population. Despite the fact that these factories are subject to regulations and inspection by the FDA, Janet Woodcock who is the director for the FDA Center for Drug Evaluation and Research, commented that “We still don’t understand the complete root cause of this problem…We understand part of it. We don’t understand all of the steps that led to this” when speaking to USA Today on this issue.

Are all blood pressure medications affected?

It is important to consult with a medical professional when being prescribed or taking any blood pressure medication.

I have been affected by this medication. What are my options?

If you or a loved one have been affected as a result of using this medication, contact our office at (303)-999-9999 or (303)-835-9342 to schedule a free consultation and speak with one of our experienced attorneys. Please also visit our practice area page on pharmaceuticals for additional medication, and read our additional blog content on blood pressure medication recalls here.

Be the first to write a comment.

Your feedback